6th Middle Eastern Oncology Meeting

Copyright Statements

Copyright Statements Slide 9. Christian Jackisch (A decade of success: trastuzumab in HER2-positive

metastatic breast cancer)Bilous. Mod Pathol 2003;16:173–82Reprinted by permission from Macmillan Publishers Ltd. Copyright © 2003

Slide 15. Christian Jackisch (A decade of success: trastuzumab in HER2-positive metastatic breast cancer)Marty. JCO 2005;23:4265–74Reprinted with permission from the American Society of Clinical Oncology

Copyright Statements Slide 17. David Miles (Innovation + strength = effective management for HER2-negative

metastatic breast cancer)O'Shaughnessy. JCO 2002;20:2812–23Reprinted with permission from the American Society of Clinical Oncology

Slide 18. David Miles (Innovation + strength = effective management for HER2-negative metastatic breast cancer)Miles. Clin Breast Cancer 2004;5:273–8Reprinted with permission. CIG Media Group, LP. Copyright © 2004. All rights reserved

Slide 22. David Miles (Innovation + strength = effective management for HER2-negative metastatic breast cancer)Poon. JCO 2001;19:1207–25Reprinted with permission from the American Society of Clinical Oncology

Slide 28. David Miles (Innovation + strength = effective management for HER2-negative metastatic breast cancer)Folkman. Cancer: Principles and Practice of Oncology(Permission requested)

Copyright Statements Slides 5–7. Marjorie Green (Treatment advances for early breast cancer: selecting

patients for optimal outcome)Perez. ASCO 2007Reprinted with kind permission from the author

Slides 20–22. Marjorie Green (Treatment advances for early breast cancer: selecting patients for optimal outcome)Slamon. SABCS 2005Reprinted with kind permission from the author

Slide 24. Marjorie Green (Treatment advances for early breast cancer: selecting patients for optimal outcome)Joensuu. NEJM 2006;354:809–20Reprinted with permission. Copyright © 2006 Massachusetts Medical Society. All rights reserved

Copyright Statements Slide 25. Marjorie Green (Treatment advances for early breast cancer: selecting

patients for optimal outcome)Baselga. Oncologist 2006;11(1):4–12Reprinted with permission. Copyright © 2006 AlphaMed Press. All rights reserved

Slides 35–37. Marjorie Green (Treatment advances for early breast cancer: selecting patients for optimal outcome)Gianni. ASCO 2007Reprinted with kind permission from the author

Slide 40. Marjorie Green (Treatment advances for early breast cancer: selecting patients for optimal outcome)Buzdar. JCO 2005;23:3676–85Reprinted with permission from the American Society of Clinical Oncology

Copyright Statements Slide 3. Nick Thatcher (The new kid on the block: bevacizumab in first-line NSCLC)

Schiller. NEJM 2002;346:92–8Reprinted with permission. Copyright © 2002 Massachusetts Medical Society. All rights reserved

Slide 9. Nick Thatcher (The new kid on the block: bevacizumab in first-line NSCLC)Jain. Nat Med 2001;7:987–9Reprinted with permission from Macmillan Publishers Ltd. Copyright © 2001

Slide 11. Nick Thatcher (The new kid on the block: bevacizumab in first-line NSCLC)Johnson. JCO 2004;22:2184–91Reprinted with permission from the American Society of Clinical Oncology

Slide 13. Nick Thatcher (The new kid on the block: bevacizumab in first-line NSCLC)Sandler. NEJM 2006;355:2542–50Reprinted with permission. Copyright © 2006 Massachusetts Medical Society. All rights reserved

Slide 42. Nick Thatcher (The new kid on the block: bevacizumab in first-line NSCLC)Dansin. CRLCC Oscar Lambret, Lille, FranceReprinted with kind permission from the author

Copyright Statements Slides 9–13,15. Romàn Pérez-Soler (First choice in second line: erlotinib in NSCLC)

Shepherd. NEJM 2005;353:123–32Reprinted with permission. Copyright © 2005 Massachusetts Medical Society. All rights reserved

Slide 17. Romàn Pérez-Soler (First choice in second line: erlotinib in NSCLC)Bezjak. JCO 2006;24:3831–7Reprinted with permission from the American Society of Clinical Oncology

Copyright Statements Slide 4. Malcolm Moore (Charting a new landscape in advanced pancreatic cancer)

Burris. JCO 1997;15:2403–13Reprinted with permission from the American Society of Clinical Oncology

Slides 14–16. Malcolm Moore (Charting a new landscape in advanced pancreatic cancer)Moore. JCO 2007;25:1960–6Reprinted with permission from the American Society of Clinical Oncology

Copyright Statements Slide 5. Frank Griesinger (Anti-VEGF therapy: a revolution in care for patients with

renal cell cancer)Linehan. J Urol 2003;170:2163–72(Permission requested) Reprinted with permission. Copyright © 2007 Elsevier

Slide 7. Frank Griesinger (Anti-VEGF therapy: a revolution in care for patients with renal cell cancer)Yang. NEJM 2003;349:427–34Reprinted with permission. Copyright © 2003 Massachusetts Medical Society. All rights reserved

Slides 13, 15, 17, 19. Frank Griesinger (Anti-VEGF therapy: a revolution in care for patients with renal cell cancer)Escudier. Lancet 2007;370:2103–11(Permission requested) Reprinted with permission. Copyright © 2007 Elsevier

Slide 25. Frank Griesinger (Anti-VEGF therapy: a revolution in care for patients with renal cell cancer)Bellmunt. Eur Urol 2007;6:484–91Reprinted with permission. Copyright © 2007 Elsevier

Copyright Statements Slide 4. Eric Van Cutsem (Forging a new standard in metastatic CRC)

Grothey. ASCO 2004Reprinted with kind permission from the author

Slide 8. Eric Van Cutsem (Forging a new standard in metastatic CRC)Hurwitz. NEJM 2004;350:2335–42Reprinted with permission. Copyright © 2004 Massachusetts Medical Society. All rights reserved

Slides 20–21, 26. Eric Van Cutsem (Forging a new standard in metastatic CRC)Schmiegel. ASCO 2007Reprinted with kind permission from the author

Slides 22–23. Eric Van Cutsem (Forging a new standard in metastatic CRC)Saltz. WCGC 2007Reprinted with kind permission from the author

Copyright Statements Slide 32. Eric Van Cutsem (Forging a new standard in metastatic CRC)

Mancuso. J Clin Invest 2006;116:2610–21Reprinted with permission from the American Society for Clinical Investigation

Slide 34. Eric Van Cutsem (Forging a new standard in metastatic CRC)Folprecht. Ann Oncol 2005;16:1311–9Reprinted with permission from Oxford University Press

Copyright Statements Slide 10. Axel Grothey (Mounting evidence in early CRC)

Van Cutsem. ASCO 2005Reprinted with kind permission from the author

Slide 11. Axel Grothey (Mounting evidence in early CRC)Ychou. ASCO 2005Reprinted with kind permission from the author

Slide 12. Axel Grothey (Mounting evidence in early CRC)Saltz. JCO 2007;25:3456–61Reprinted with permission from the American Society of Clinical Oncology

Slide 13. Axel Grothey (Mounting evidence in early CRC)Andre. NEJM 2004;350:2343–5Reprinted with permission. Copyright © 2004 Massachusetts Medical Society. All rights reserved

Slide 26. Axel Grothey (Mounting evidence in early CRC)Scheithauer. Ann Oncol 2003;14:1735–43Reprinted with permission from Oxford University Press

Copyright Statements Slide 32. Axel Grothey (Mounting evidence in early CRC)

Cassidy. ASCO 2004Reprinted with kind permission from the author

Slides 35, 36. Axel Grothey (Mounting evidence in early CRC)Inai. Am J Pathol 2004;165:35–52Reprinted with permission from the American Society for Investigative Pathology

Slide 37. Axel Grothey (Mounting evidence in early CRC)Wildiers. Br J Cancer 2003;88:1979–86Reprinted by permission from Macmillan Publishers Ltd. Copyright © 2003

Slide 38. Axel Grothey (Mounting evidence in early CRC)Mancuso. J Clin Invest 2006;116:2610–21Reprinted with permission from the American Society for Clinical Investigation

Copyright Statements Slides 24–26. Werner Scheithauer (Capecitabine: the new standard chemotherapy in

advanced gastric cancer?)Cunningham. NEJM 2008;358:36–46Reprinted with permission. Copyright © 2008 Massachusetts Medical Society. All rights reserved

Copyright Statements Slide 6, 7 Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy

should not be delayed)Coiffier. ASCO 2007Reprinted with kind permission from the author

Slide 8, 16. Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy should not be delayed)Pfreundschuh. Lancet Oncol 2008;9:105–16(Permission requested) Reprinted with permission. Copyright © 2007 Elsevier

Slide 9. Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy should not be delayed)Feugier. JCO 2005;23:4117–26(Permission requested) Reprinted with permission from the American Society of Clinical Oncology

Slides 11, 12 Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy should not be delayed)Habermann. JCO 2006;24:3121–7(Permission requested) Reprinted with permission from the American Society of Clinical Oncology

Copyright Statements Slides 11, 12 Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy

should not be delayed)Habermann. JCO 2006;24:3121–7(Permission requested) Reprinted with permission from the American Society of Clinical Oncology

Slide 14. Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy should not be delayed)Pfreundschuh. Lancet Oncol 2006;7:379–91(Permission requested) Reprinted with permission. Copyright © 2006 Elsevier

Slide 23. Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy should not be delayed)Tilly. Blood 2003;102:4284–9(Permission requested) Reprinted with permission. Copyright © 2003 American Society of Hematology

Copyright Statements Slide 44. Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy

should not be delayed)Khouri. JCO 2005;23:2240–7Reprinted with permission from the American Society of Clinical Oncology

Slide 52–54. Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy should not be delayed)Haioun. ASCO 2007Reprinted with kind permission from the author

Slide 55. Bertrand Coiffier (Rituximab in aggressive NHL: why combination therapy should not be delayed)Rice. Blood 2007;110:385a (Abstract 1280)(Permission requested) Reprinted with permission. Copyright © 2007 American Society of Hematology

Copyright Statements Slide 4. Christian Buske (Indolent NHL: a survival benefit with rituximab-based

therapy)Ardeshna. Lancet 2003;362:516–22(Permission requested) Reprinted with permission. Copyright © 2003 Elsevier

Slide 10. Christian Buske (Indolent NHL: a survival benefit with rituximab-based therapy)Marcus. Blood 2005;105:1417–23(Permission requested) Reprinted with permission. Copyright © 2005 American Society of Hematology

Slides 13, 14. Christian Buske (Indolent NHL: a survival benefit with rituximab-based therapy)Hiddemann. Blood 2005;106:3725–32Reprinted with permission. Copyright © 2005 American Society of Hematology

Copyright Statements Slides 17–19. Christian Buske (Indolent NHL: a survival benefit with rituximab-based

therapy)Herold. JCO 2007;25:1986–92Reprinted with permission from the American Society of Clinical Oncology

Slide 26. Christian Buske (Indolent NHL: a survival benefit with rituximab-based therapy)Schulz. J Natl Cancer Inst 2007;99:706–14Reprinted with permission from Oxford University Press

Slide 5. Christian Buske (Indolent NHL: a survival benefit with rituximab-based therapy)Horning. Semin Oncol 1993;20(5):75–8(Permission requested) Reprinted with permission. Copyright © 1993 Elsevier

Copyright Statements Slide 8–10. Marinus van Oers (Maintenance treatment in follicular lymphoma:

indications and considerations)Van Oers. Blood 2006;108:3295–301Reprinted with permission. Copyright © 2006 American Society of Hematology

Slide 15. Marinus van Oers (Maintenance treatment in follicular lymphoma: indications and considerations)Forstpointner. Blood 2006;108:4003–8Reprinted with permission. Copyright © 2006 American Society of Hematology

Slide 16. Marinus van Oers (Maintenance treatment in follicular lymphoma: indications and considerations)Hainsworth. JCO 2005;23:1088–95Reprinted with permission from the American Society of Clinical Oncology

Copyright Statements Slide 8. Stephen Mulligan (CLL treatment today and tomorrow: the role of rituximab)

Catovsky. Lancet 2007;370:230–9(Permission requested) Reprinted with permission. Copyright © 2007 Elsevier

Slide 9. Stephen Mulligan (CLL treatment today and tomorrow: the role of rituximab)Binder. Blood 2006;108:1975–8(Permission requested) Reprinted with permission. Copyright © 2006 American Society of Hematology

Slide 10. Stephen Mulligan (CLL treatment today and tomorrow: the role of rituximab)Cragg. Curr Dir Autoimmun 2005;8:140–74Reprinted with permission. Copyright © 2005 S. Karger AG

Slide 16. Stephen Mulligan (CLL treatment today and tomorrow: the role of rituximab)Byrd. Blood 2005;105:49–53(Permission requested) Reprinted with permission. Copyright © 2005 American Society of Hematology

Copyright Statements Slide 9–11. John Gribben (Management of relapsed CLL: why rituximab?)

Wierda. JCO 2005;23:4070–8Reprinted with permission from the American Society of Clinical Oncology

Slide 14. John Gribben (Management of relapsed CLL: why rituximab?)Wierda. Cancer 2006;106:337–45(Permission requested) Reprinted with permission. John Wiley & Sons Ltd

Slide 24. John Gribben (Management of relapsed CLL: why rituximab?)Gribben. Blood 2005;106:4389–96Reprinted with permission. Copyright © 2005 American Society of Hematology